Open AccessExploring the role of technitium-99m dimercaptosuccinyl acid (V) scan in medullary carcinoma thyroid patients with postoperative persistent hypercalcitoninemia in the era of positron emission tomography-computerized tomography
Author(s) -
Arvind Krishnamurthy,
Ram Kumar,
Praveen Ravishankaran,
Vijayalaksmi Ramshankar,
Ahamed Sultan Balkis Begum,
Gomadam Kuppuswamy Rangarajan
Publication year - 2014
Publication title -
indian journal of nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 13
eISSN - 0972-3919
pISSN - 0974-0244
DOI - 10.4103/0972-3919.136562
Subject(s) - medicine , calcitonin , thyroid carcinoma , positron emission tomography , medullary cavity , pheochromocytoma , nuclear medicine , technetium 99m , radiology , tomography , medullary thyroid cancer , magnetic resonance imaging , positron emission , thyroid , scintigraphy
Many radio-pharmaceuticals have been used over the years to localize the recurrences in patients with medullary carcinoma thyroid (MCT), including iodine-131-metaiodobenzylguanidine, thallium-201, technitium-99m dimercaptosuccinyl acid [Tc-99m DMSA (V)], Tc-99m methoxyisobutylisonitril, Tc-99 ethylenediamine diacetic acid/hydrazinonicotinyl-Tyr (3)-octreotide, and In-111 diethylenetriaminepenta-acetic acid-octreotide with varying sensitivities and specificities.